GT Biopharma Reports Second Quarter 2025 Financial Results

SAN FRANCISCO, CALIFORNIA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE^® platform, today announced second quarter 2025 financial results for the period ended June 30, 2025.

Read more at globenewswire.com